 | | | | A weight-loss firm’s pivot into neurorehabilitation is sending its shares soaring 80%+, a used car giant is crashing after posting poor earnings, and a furniture maker’s shares are rising after it posted a strong earnings bounceback. Read on to find out more. | |
|
| | | | | What to Watch | Earnings: | | Economic Reports: | Initial jobless claims [Apr 5]: 8:30 am Consumer price index [Mar]: 8:30 am CPI year over year: 8:30 am Core CPI [Mar]: 8:30 am Core CPI year over year: 8:30 am Dallas Fed President Lorie Logan opening remarks: 9:30 am Fed Governor Michelle Bowman testifies to Senate: 10:00 am Kansas City Fed President Jeff Schmid will speak at 10:00 am Philadelphia Fed President Patrick Harker will speak at 12:00 pm Chicago Fed President Austan Goolsbee will speak at 12:00 pm Monthly U.S. federal budget: 2:00 pm Boston Fed President Susan Collins will speak at 4:00 pm
|
|
| | Clean Energy (Sponsored) | On Behalf of Azincourt Energy Corp | | | Five years ago, Uranium Energy Corp. (UEC) was a small uranium junior trading at just $0.60. | Most investors ignored it. | Then, the uranium market exploded. | UEC’s stock skyrocketed 2,500 percent, transforming early investors into millionaires. | Now, the market is hunting for the next UEC. | One tiny uranium junior is sitting on prime assets in the world’s richest uranium region. | Drill results confirm uranium mineralization, with more exploration underway. | Global nuclear expansion is fueling long-term demand for uranium. | The US is desperate for domestic uranium supply—creating a major opportunity. | With billionaire-backed nuclear investments and a global energy crunch, this company could be the next big uranium success story. | Find out why investors are paying attention to this stock. | *Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities. |
|
| | Used Car Retail | CarMax Beats on Sales But Trails on Profit as Stock Sinks | | Shares of CarMax (NYSE: KMX) are down 7% during premarket trading as the used car retailer reported mixed results for the final quarter of its fiscal year 2025. | While revenue came in ahead of Wall Street projections, earnings per share fell short of expectations. | The company posted a net revenue of $6.0 billion for the quarter ending February 28, representing a 6.7% year-over-year increase. | This was fueled by a 6.2% growth in retail used unit sales and a 5.1% rise in comparable store sales. | Earnings per share rose to $0.58, marking an 81.3% jump from last year but missing the $0.647 consensus forecast. | Gross profit climbed nearly 14% to $667.9 million, with retail gross profit per unit hitting a record $2,322. | CarMax also saw strong wholesale results, and revenue from extended service plans improved slightly. | CarMax acquired 269,000 vehicles during the quarter, with a 15.3% increase in purchases from consumers and dealers, bolstering its inventory. SG&A expenses increased modestly by 5.1% to $610.5 million. | Looking ahead, the company plans to open six new stores and four reconditioning centers in fiscal 2026, backed by $575 million in capital investment. | Management is targeting double-digit earnings growth driven by continued expansion and market share gains. |
|
| | Beverage Alcohol | Constellation Brands Swings to Q4 Loss, Unveils Major Wine Brand Divestiture | | Constellation Brands (NYSE: STZ) reported a net loss of $375.3 million for the fourth quarter of fiscal 2025, a sharp reversal from the $392.4 million profit recorded a year earlier. | The quarterly loss amounted to $2.09 per share, though adjusted earnings per share improved to $2.63 from $2.30 last year, beating analyst expectations. | Shares of Constellation Brands are down 2.40% in premarket trading. | Quarterly revenue rose slightly to $2.16 billion, with organic sales in its Wine and Spirits segment up over 11%, helped by favorable product mix, distribution agreements, and increased demand in Canada and other international markets. | In a significant strategic move, the company will divest its remaining mass-market wine brands—including Woodbridge, Meiomi, and Robert Mondavi Private Selection—to The Wine Group. | The transaction, which includes vineyards and production facilities, is expected to finalize shortly after the first quarter of fiscal 2026. | Looking ahead, Constellation expects fiscal 2026 adjusted EPS between $12.60 and $12.90—below analysts’ average forecast of $13.94. | The company also revealed a new $4-billion stock buyback program and anticipates free cash flow of up to $1.6 billion next year. | Additionally, the company plans to invest $2 billion through 2028 to expand brewing capacity in Mexico to 55 million hectoliters, aligning with growth in its high-end beer segment. |
|
| | | | Modular Furniture | Lovesac Surges After Q4 Tops Expectations Across Key Metrics | | Shares of Lovesac (NASDAQ: LOVE) are jumping over 16% this morning as the furniture company reported stronger-than-anticipated results for the final quarter of calendar year 2024. | Despite a slight year-over-year decline in revenue, the company comfortably exceeded Wall Street forecasts on revenue, profit, and EBITDA. | Revenue for the fourth quarter came in at $241.5 million, down 3.6% from the previous year but surpassing analyst expectations by nearly 5%. | Earnings per share on a GAAP basis reached $2.13, beating the consensus estimate of $1.87 by 13.7%. Adjusted EBITDA stood at $53.87 million, reflecting a margin of 22.3%. | Management has issued upbeat guidance for fiscal year 2026, projecting $725 million in revenue and $54 million in EBITDA at the midpoint—both slightly ahead of consensus. | Operating margin expanded to 19.7%, up from 16.1% a year earlier, suggesting improved efficiency despite soft sales. | Lovesac credited its performance to operational discipline and the continued appeal of its modular furniture offerings. | While macroeconomic headwinds have softened broader demand in the home furnishing sector, the company’s guidance implies moderate growth ahead. |
|
| | Movers and Shakers | | ReShape Lifesciences, Inc. [RSLS] - Last Close: $0.34 | ReShape Lifesciences is a weight loss firm that is expanding into the neurorehabilitation space. | The stock is rising 86% in premarket trading after the firm announced that it is partnering with Israel-based Motion Informatics to exclusively distribute its FDA-cleared Stimel-03 device in the U.S. | My Take: ReShape is pivoting smartly into high-growth health tech with a strong partner. If execution aligns with innovation, this move could rejuvenate investor confidence and bring long-term upside. Keep this stock on your radar. |
|
|
|
| Pasithea Therapeutics Corp. [KTTA] - Last Close: $1.09 | Pasithea Therapeutics is a clinical-stage biotech firm focused on innovative therapies for neurological and oncological conditions. | Its shares are rising 42% today after announcing a positive recommendation from its Safety Review Committee (SRC) to escalate to the next dose level in its Phase 1 clinical trial of PAS-004, a treatment candidate for advanced cancer. | My Take: KTTA is still early-stage, but this progress in oncology adds meaningful value. If PAS-004 keeps showing promise, it could evolve into a key asset in Pasithea’s pipeline. Keep a close watch on this stock. |
|
|
|
| Keros Therapeutics, Inc. [KROS] - Last Close: $10.33 | Keros Therapeutics is a clinical-stage biopharmaceutical company. | Its shares are surging over 17% in premarket trading after the company announced it is exploring strategic alternatives, including a potential sale, to maximize shareholder value. | My Take: Keros has a promising pipeline, especially in rare diseases, but limited commercial traction to date. A sale to a larger biotech player could fast-track development and reward shareholders handsomely. Watch for further news on a sale. |
|
|
|
| | Tech Giants in the Making (Sponsored) | | | The original Magnificent Seven changed the investing landscape, but the next generation of tech powerhouses is emerging. | While everyone is focused on Apple and Microsoft, smart investors are shifting their attention to these overlooked winners. | These 7 stocks have the same growth potential, strong balance sheets, and market dominance—just without the massive valuations yet. | (By clicking the link above, you agree to receive emails from MarketBeat. You can opt out at any time. - Privacy Policy) | Get ahead of the curve with this exclusive free report. | Click here to see the full list.
(By clicking the link above, you agree to receive emails from MarketBeat. You can opt out at any time. - Privacy Policy) |
|
| | | | That’s all for today. Thank you for reading. If you have any feedback, please reply to this email. | Best Regards, | — Adam Garcia
Elite Trade Club |
|
| | | | Click here to get our daily newsletter straight to your cell for free. | P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. |
| |
|
|
|
